Suppr超能文献

非小细胞肺癌中动态F-氟米索硝唑PET数据的药代动力学分析

Pharmacokinetic Analysis of Dynamic F-Fluoromisonidazole PET Data in Non-Small Cell Lung Cancer.

作者信息

Schwartz Jazmin, Grkovski Milan, Rimner Andreas, Schöder Heiko, Zanzonico Pat B, Carlin Sean D, Staton Kevin D, Humm John L, Nehmeh Sadek A

机构信息

Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York

Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.

出版信息

J Nucl Med. 2017 Jun;58(6):911-919. doi: 10.2967/jnumed.116.180422. Epub 2017 Feb 23.

Abstract

Hypoxic tumors exhibit increased resistance to radiation, chemical, and immune therapies. F-fluoromisonidazole (F-FMISO) PET is a noninvasive, quantitative imaging technique used to evaluate the magnitude and spatial distribution of tumor hypoxia. In this study, pharmacokinetic analysis (PKA) of F-FMISO dynamic PET extended to 3 h after injection is reported for the first time, to our knowledge, in stage III-IV non-small cell lung cancer (NSCLC) patients. Sixteen patients diagnosed with NSCLC underwent 2 PET/CT scans (1-3 d apart) before radiation therapy: a 3-min static F-FDG and a dynamic F-FMISO scan lasting 168 15 min. The latter data were acquired in 3 serial PET/CT dynamic imaging sessions, registered with each other and analyzed using pharmacokinetic modeling software. PKA was performed using a 2-tissue, 3-compartment irreversible model, and kinetic parameters were estimated for the volumes of interest determined using coregistered F-FDG images for both the volume of interest-averaged and the voxelwise time-activity curves for each patient's lesions, normal lung, and muscle. We derived average values of F-FMISO kinetic parameters for NSCLC lesions as well as for normal lung and muscle. We also investigated the correlation between the trapping rate () and delivery rate (), influx rate ( ) constants, and tissue-to-blood activity concentration ratios (TBRs) for all tissues. Lesions had trapping rates 1.6 times larger, on average, than those of normal lung and 4.4 times larger than those in muscle. Additionally, for almost all cases, and had a significant strong correlation for all tissue types. The TBR- correlation was less straightforward, showing a moderate to strong correlation for only 41% of lesions. Finally, - voxelwise correlations for tumors were varied, but negative for 76% of lesions, globally exhibiting a weak inverse relationship (average R -0.23 0.39). However, both normal tissue types exhibited significant positive correlations for more than 60% of patients, with 41% having moderate to strong correlations (R 0.5). All lesions showed distinct F-FMISO uptake. Variable F-FMISO delivery was observed across lesions, as indicated by the variable values of the kinetic rate constant Except for 3 cases, some degree of hypoxia was apparent in all lesions based on their nonzero values.

摘要

缺氧肿瘤对放疗、化疗和免疫治疗的耐药性增强。F-氟米索硝唑(F-FMISO)PET是一种用于评估肿瘤缺氧程度和空间分布的非侵入性定量成像技术。据我们所知,本研究首次报道了对III-IV期非小细胞肺癌(NSCLC)患者注射F-FMISO后动态PET进行长达3小时的药代动力学分析(PKA)。16例诊断为NSCLC的患者在放疗前接受了2次PET/CT扫描(间隔1-3天):一次3分钟的静态F-FDG扫描和一次持续168±15分钟的动态F-FMISO扫描。后者的数据是在3次连续的PET/CT动态成像过程中采集的,相互配准并使用药代动力学建模软件进行分析。PKA采用双组织三室不可逆模型进行,动力学参数是针对使用配准后的F-FDG图像确定的感兴趣体积进行估计的,用于每个患者病变、正常肺和肌肉的感兴趣体积平均和体素时间-活性曲线。我们得出了NSCLC病变以及正常肺和肌肉的F-FMISO动力学参数的平均值。我们还研究了所有组织的摄取率()、输送率()、流入率()常数以及组织与血液活性浓度比(TBR)之间的相关性。病变的摄取率平均比正常肺大1.6倍,比肌肉大4.4倍。此外,几乎在所有情况下,所有组织类型的和都有显著的强相关性。TBR-相关性不太直接,仅41%的病变显示出中度到强的相关性。最后,肿瘤的-体素相关性各不相同,但76%的病变为负相关,总体呈现出较弱的负相关关系(平均R -0.23±0.39)。然而,两种正常组织类型在超过60%的患者中显示出显著的正相关,41%的患者具有中度到强的相关性(R 0.5)。所有病变均显示出明显的F-FMISO摄取。如动力学速率常数的可变值所示,各病变间观察到F-FMISO输送情况各异。除3例病例外,基于其非零值,所有病变均表现出一定程度的缺氧。

相似文献

1
Pharmacokinetic Analysis of Dynamic F-Fluoromisonidazole PET Data in Non-Small Cell Lung Cancer.
J Nucl Med. 2017 Jun;58(6):911-919. doi: 10.2967/jnumed.116.180422. Epub 2017 Feb 23.
2
F-Fluoromisonidazole Kinetic Modeling for Characterization of Tumor Perfusion and Hypoxia in Response to Antiangiogenic Therapy.
J Nucl Med. 2017 Oct;58(10):1567-1573. doi: 10.2967/jnumed.117.190892. Epub 2017 Mar 30.
5
Multiparametric Imaging of Tumor Hypoxia and Perfusion with F-Fluoromisonidazole Dynamic PET in Head and Neck Cancer.
J Nucl Med. 2017 Jul;58(7):1072-1080. doi: 10.2967/jnumed.116.188649. Epub 2017 Feb 9.
6
F-fluoromisonidazole uptake in advanced stage non-small cell lung cancer: A voxel-by-voxel PET kinetics study.
Med Phys. 2017 Sep;44(9):4665-4676. doi: 10.1002/mp.12416. Epub 2017 Jul 21.
8
Inter-operator variability in compartmental kinetic analysis of F-fluoromisonidazole dynamic PET.
Clin Imaging. 2018 May-Jun;49:121-127. doi: 10.1016/j.clinimag.2017.12.015. Epub 2018 Jan 12.
9
High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
J Nucl Med. 2013 Feb;54(2):201-7. doi: 10.2967/jnumed.112.109330. Epub 2013 Jan 15.

引用本文的文献

3
Advances in PET and MRI imaging of tumor hypoxia.
Front Med (Lausanne). 2023 Feb 9;10:1055062. doi: 10.3389/fmed.2023.1055062. eCollection 2023.
4
Kinetic Evaluation of the Hypoxia Radiotracers [F]FMISO and [F]FAZA in Dogs with Spontaneous Tumors Using Dynamic PET/CT Imaging.
Nucl Med Mol Imaging. 2023 Feb;57(1):16-25. doi: 10.1007/s13139-022-00780-4. Epub 2022 Oct 11.
6
Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography.
Front Oncol. 2021 Nov 19;11:772530. doi: 10.3389/fonc.2021.772530. eCollection 2021.
7
Hypoxia in Lung Cancer Management: A Translational Approach.
Cancers (Basel). 2021 Jul 8;13(14):3421. doi: 10.3390/cancers13143421.
8
Hypoxia and the phenomenon of immune exclusion.
J Transl Med. 2021 Jan 6;19(1):9. doi: 10.1186/s12967-020-02667-4.

本文引用的文献

1
Imaging Hypoxia with ¹⁸F-Fluoromisonidazole: Challenges in Moving to a More Complicated Analysis.
J Nucl Med. 2016 Apr;57(4):497-8. doi: 10.2967/jnumed.115.171694. Epub 2016 Feb 18.
2
Feasibility of 18F-Fluoromisonidazole Kinetic Modeling in Head and Neck Cancer Using Shortened Acquisition Times.
J Nucl Med. 2016 Mar;57(3):334-41. doi: 10.2967/jnumed.115.160168. Epub 2015 Nov 25.
3
Improved correction for the tissue fraction effect in lung PET/CT imaging.
Phys Med Biol. 2015 Sep 21;60(18):7387-402. doi: 10.1088/0031-9155/60/18/7387. Epub 2015 Sep 9.
4
Imaging tumour hypoxia with positron emission tomography.
Br J Cancer. 2015 Jan 20;112(2):238-50. doi: 10.1038/bjc.2014.610. Epub 2014 Dec 16.
5
Kinetic modeling in PET imaging of hypoxia.
Am J Nucl Med Mol Imaging. 2014 Sep 6;4(6):490-506. eCollection 2014.
6
The importance of correction for tissue fraction effects in lung PET: preliminary findings.
Eur J Nucl Med Mol Imaging. 2011 Dec;38(12):2238-46. doi: 10.1007/s00259-011-1906-x. Epub 2011 Aug 27.
7
Hypoxia in models of lung cancer: implications for targeted therapeutics.
Clin Cancer Res. 2010 Oct 1;16(19):4843-52. doi: 10.1158/1078-0432.CCR-10-1206. Epub 2010 Sep 21.
8
Pharmacokinetic analysis of hypoxia (18)F-fluoromisonidazole dynamic PET in head and neck cancer.
J Nucl Med. 2010 Jan;51(1):37-45. doi: 10.2967/jnumed.109.067009. Epub 2009 Dec 15.
9
Evaluation of a compartmental model for estimating tumor hypoxia via FMISO dynamic PET imaging.
Phys Med Biol. 2009 May 21;54(10):3083-99. doi: 10.1088/0031-9155/54/10/008. Epub 2009 May 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验